SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

28.66 1.85

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.9

Max

28.8

Põhinäitajad
By Trading Economics
Sissetulek	-13M -19M
Müük	-24M 3M
Kasumimarginaal	-618.236
Töötajad	103
EBITDA	-14M -13M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+20.4% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	20. mai 2026

Turustatistika
By TradingEconomics
Turukapital	47M 1.4B
Eelmine avamishind	26.81
Eelmine sulgemishind	28.66

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 23:53 UTC

Tulu

Naver Posts Weaker First-Quarter Earnings

29. apr 2026, 23:41 UTC

Kuumad aktsiad

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. apr 2026, 23:55 UTC

Tulu

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. apr 2026, 23:54 UTC

Tulu

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. apr 2026, 23:52 UTC

Tulu

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. apr 2026, 23:51 UTC

Tulu

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. apr 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. apr 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. apr 2026, 23:22 UTC

Tulu

China Longyuan 1Q Net CNY1.70B, Down 14%

29. apr 2026, 23:22 UTC

Tulu

China Longyuan: Power Generation Down 2.9% as of End-March

29. apr 2026, 23:20 UTC

Tulu

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. apr 2026, 23:20 UTC

Tulu

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss Narrows>000002.SZ

29. apr 2026, 23:18 UTC

Tulu

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. apr 2026, 23:17 UTC

Tulu

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. apr 2026, 23:13 UTC

Tulu

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. apr 2026, 23:12 UTC

Tulu

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. apr 2026, 23:04 UTC

Tulu

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. apr 2026, 23:04 UTC

Tulu

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

20.4% tõus

12 kuu keskmine prognoos

Keskmine 34 EUR 20.4%

Kõrge 34 EUR

Madal 34 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.